WHO approves trials for two new Ebola vaccines
WHO approves trials for two new Ebola vaccines
WHO approves trials for two new Ebola vaccines
Key points
اہم نکات
मुख्य बातें
- The World Health Organization has approved clinical trials for two new Ebola vaccines as doctors fight the largest outbreak in the history of the Democratic Republic of the Congo.
- The two vaccines, ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469, are designed specifically for the Bundibugyo strain, which has killed more than 5,300 people since May.
- They will be added to the ongoing Tumaini trial, which began last month using the Ervebo vaccine, approved for the Zaire strain but not for Bundibugyo.
- The World Health Organization has approved clinical trials for two new Ebola vaccines as doctors fight the largest outbreak in the history of the Democratic Republic of the Congo.
- The two vaccines, ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469, are designed specifically for the Bundibugyo strain, which has killed more than 5,300 people since May.
- They will be added to the ongoing Tumaini trial, which began last month using the Ervebo vaccine, approved for the Zaire strain but not for Bundibugyo.
- The World Health Organization has approved clinical trials for two new Ebola vaccines as doctors fight the largest outbreak in the history of the Democratic Republic of the Congo.
- The two vaccines, ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469, are designed specifically for the Bundibugyo strain, which has killed more than 5,300 people since May.
- They will be added to the ongoing Tumaini trial, which began last month using the Ervebo vaccine, approved for the Zaire strain but not for Bundibugyo.
The World Health Organization has approved clinical trials for two new Ebola vaccines as doctors fight the largest outbreak in the history of the Democratic Republic of the Congo. The two vaccines, ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469, are designed specifically for the Bundibugyo strain, which has killed more than 5,300 people since May. They will be added to the ongoing Tumaini trial, which began last month using the Ervebo vaccine, approved for the Zaire strain but not for Bundibugyo. The DRC's National Institute for Biomedical Research is leading the trial, and results are expected in early 2027.
The World Health Organization has approved clinical trials for two new Ebola vaccines as doctors fight the largest outbreak in the history of the Democratic Republic of the Congo. The two vaccines, ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469, are designed specifically for the Bundibugyo strain, which has killed more than 5,300 people since May. They will be added to the ongoing Tumaini trial, which began last month using the Ervebo vaccine, approved for the Zaire strain but not for Bundibugyo. The DRC's National Institute for Biomedical Research is leading the trial, and results are expected in early 2027.
The World Health Organization has approved clinical trials for two new Ebola vaccines as doctors fight the largest outbreak in the history of the Democratic Republic of the Congo. The two vaccines, ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469, are designed specifically for the Bundibugyo strain, which has killed more than 5,300 people since May. They will be added to the ongoing Tumaini trial, which began last month using the Ervebo vaccine, approved for the Zaire strain but not for Bundibugyo. The DRC's National Institute for Biomedical Research is leading the trial, and results are expected in early 2027.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।